Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
7
Deaths Reported
5380.0%
Death Rate

Active Ingredients

Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid

Administration Routes

SubcutaneousUnknownIntramuscular

Species Affected

Cattle 13

Most Affected Breeds

Cattle (other) 5
Crossbred Bovine/Cattle 3
Cattle (unknown) 3
Aberdeen Angus 2

Most Reported Reactions

Death 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Recumbency 3
Nasal discharge 3
Abortion 3
Death by euthanasia 3
Lack of efficacy - NOS 2
NT - Abnormal necropsy finding NOS 2
Other abnormal test result NOS 2
Sinusitis 1
Malaise 1
Partial lack of efficacy 1

Outcome Breakdown

Died
7 (38.9%)
Recovered/Normal
5 (27.8%)
Outcome Unknown
3 (16.7%)
Euthanized
2 (11.1%)
Ongoing
1 (5.6%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 7
Case-fatality rate (reported events) 5380.0%
Distinct species in reports 1
Distinct breeds in reports 4
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid, including 7 reports in which the animal died — a 5380.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid. Reported administration routes include Subcutaneous, Unknown, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid reports are Cattle (13 reports), with Cattle accounting for the largest share. Within those species, Cattle (other) (5), Crossbred Bovine/Cattle (3), Cattle (unknown) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid are Death (5), Lethargy (see also Central nervous system depression in 'Neurological') (5), Recumbency (3), Nasal discharge (3). Of the 18 reports with a coded outcome, Died is the leading category at 38.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D Bacterin-Toxoid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial